Berita Kesehatan
Chymase-1: a “MAST”-er switch in COPD?
Rabu, 14 Des 2022 11:50:37

Corrine R. Kliment, Reinoud Gosens

European Respiratory Journal 2022 60: 2201356; DOI: 10.1183/13993003.01356-2022


Chronic inflammation of the airways and lung tissue is an important feature of COPD. In recent years, a role for mast cells has emerged in numerous diseases, including COPD [1–4]. Mast cells are long-lived tissue-resident immune cells that secrete proteases and chymases (such as CMA1), interact with antigen-presenting cells and mediate immune responses [5]. These granule-filled cells were first described by Ehrlich [6] in 1878. The role of mast cells in lung disease has been shown in asthma [7], but remains relatively unexplored in COPD. In patients with COPD, there are changes in the density and localisation of tissue-resident mast cells [1, 2, 4, 8].

Mast cells are emerging as an important cell type in the chronic inflammation present in COPD and are poised to be the focus of future therapeutic approaches.


  • Conflict of interest: C.R. Kliment declares no competing interests.

  • Conflict of interest: R. Gosens declares grant funding to their institution from Aquilo BV, Boehringer Ingelheim and Sanofi-Genzyme, in the 36 months prior to manuscript submission.

  • Received July 7, 2022.
  • Accepted July 7, 2022.
  • Copyright ©The authors 2022. For reproduction rights and permissions contact